JPRN-jRCT2080222293未知3 期
A phase 3, multicenter, open-label study of naldemedine in cancer patients with opioid-induced constipation - extension study
适应症
试验速览
- 阶段
- 3 期
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients who participated in the phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of naldemedine in cancer patients with opioid-induced constipation and completed the treatment period, etc.
排除标准
- •Patients with constipation potentially attributable to causes other than opioid analgesics
- •Patients with hepatic or renal disorders, etc
研究者
相似试验
未知
3 期
A phase 3, multicenter, open-label study of naldemedine in patients with non-malignant pain and opioid-induced constipatioJPRN-jRCT2080222393SHIONOGI & CO., LTD.40
未知
3 期
A phase 3, multicenter, open-label study of naldemedine in patients with non-malignant chronic pain and opioid-induced constipation receiving S-8117 (Oxycodone hydrochloride hydrate)Patients with non-malignant painJPRN-jRCT2080222556SHIONOGI & CO., LTD.10
进行中（未招募）
1 期
ong-term safety and efficacy of BIVV001 in Previously Treated Patients with hemophilia AMedDRA version: 20.0Level: LLTClassification code 10060612Term: Hemophilia ASystem Organ Class: 100000004850Hemophilia AEUCTR2020-002215-22-NLBioverativ Therapeutics Inc.90
进行中（未招募）
3 期
ong-term safety and efficacy of BIVV001 in Previously Treated Patients with hemophilia AHemophilia AJPRN-jRCT2031210133Tanaka Tomoyuki262
进行中（未招募）
1 期
ong-term safety and efficacy of BIVV001 in Previously Treated Patients with hemophilia AHemophilia AEUCTR2020-002215-22-BEBioverativ Therapeutics Inc.267